Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.Niels W.C.J. van de Donk, María‐Victoria Mateos, Danielle Trancucci et al.|Journal of Clinical Oncology|2023Cited by 28
Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab TreatmentJia Zhou, Weirong Wang, Deeksha Vishwamitra et al.|Blood|2023Cited by 6
P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1Niels W.C.J. van de Donk, María‐Victoria Mateos, Alfred L. Garfall et al.|HemaSphere|2023Cited by 5
Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab TreatmentJia Zhou, Weirong Wang, Deeksha Vishwamitra et al.|Unknown|2024Cited by 0